Cipla Limited (NSE: CIPLA, BSE: 500087) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,07,048 Cr, it ranks #98 by market cap among the 6,137 Indian listed companies on FinBizNet, and #4 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,338.00 (as of 25 Oct 2026), the share price is 17.7% below its 52-week high of ₹1,625.10 and 14.8% above its 52-week low of ₹1,165.70. The share price is down 14.7% over one year and down 5.1% over three months.
| Current Price | ₹1,338.00 |
|---|---|
| Market Cap | ₹1,07,048 Cr |
| NSE Symbol | CIPLA |
| BSE Code | 500087 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 27.6 |
| Return on Equity | 11.74% |
| Return on Assets | 7.58% |
| 52-Week Range | ₹1,165.70 – ₹1,625.10 |
| 1-Year Price Change | -14.7% |
| 3-Month Price Change | -5.1% |
| Beta (1Y) | 0.02 |
| Dividend Yield | 0.98% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.cipla.com |
| Revenue | ₹7,119 Cr |
|---|---|
| Net Profit | ₹787 Cr |
| Net Margin | 11.1% |
| EPS (Basic) | ₹9.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
1. Pharmaceuticals-This segment develops, manufactures, sells, and distributes generic or branded generic medicines, as well as active pharmaceutical ingredients. 2. New Ventures-This segment engages in the consumer healthcare, biosimilars, and specialty businesses. 3. Inter Segment Revenue-0 4. Segment Adjustment-0
1. Pharmaceutical and Related Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Cipla Limited is trading at ₹1,338.00, with a market capitalisation of ₹1,07,048 Cr.
Cipla Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Cipla Limited has a P/E of 27.6 and a return on equity of 11.74%.
Cipla Limited is listed on the NSE under the symbol CIPLA and on the BSE under the scrip code 500087.
Cipla Limited's share price is down 14.7% over one year and down 5.1% over three months. Its 52-week range is ₹1,165.70 to ₹1,625.10.
In Q1 FY27, Cipla Limited reported revenue of ₹7,119 Cr and net profit of ₹787 Cr, with basic EPS of ₹9.77 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.